Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV Infections | 20 | 2021 | 11620 | 0.89 | Why? |
| Pravastatin | 2 | 2017 | 10 | 0.87 | Why? |
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2018 | 31 | 0.75 | Why? |
| Anal Canal | 2 | 2018 | 367 | 0.71 | Why? |
| Cervix Uteri | 1 | 2018 | 146 | 0.67 | Why? |
| Cultural Diversity | 1 | 2019 | 220 | 0.66 | Why? |
| Quinolines | 3 | 2018 | 403 | 0.64 | Why? |
| Herpesviridae | 1 | 2017 | 100 | 0.64 | Why? |
| Women, Working | 1 | 2017 | 96 | 0.63 | Why? |
| Anticholesteremic Agents | 2 | 2017 | 186 | 0.60 | Why? |
| Herpesviridae Infections | 1 | 2017 | 172 | 0.59 | Why? |
| Infectious Disease Medicine | 1 | 2017 | 311 | 0.55 | Why? |
| Social Discrimination | 1 | 2017 | 269 | 0.52 | Why? |
| DNA, Viral | 3 | 2018 | 2521 | 0.42 | Why? |
| Dyslipidemias | 1 | 2017 | 791 | 0.41 | Why? |
| Minority Groups | 2 | 2019 | 1631 | 0.41 | Why? |
| Pharynx | 1 | 2017 | 1544 | 0.40 | Why? |
| Papillomavirus Infections | 1 | 2018 | 861 | 0.39 | Why? |
| Chronic Pain | 1 | 2018 | 736 | 0.38 | Why? |
| CD4 Lymphocyte Count | 7 | 2019 | 1517 | 0.38 | Why? |
| Hepatitis B | 1 | 2014 | 888 | 0.30 | Why? |
| Opioid-Related Disorders | 1 | 2018 | 1185 | 0.30 | Why? |
| Cholesterol, LDL | 3 | 2018 | 499 | 0.28 | Why? |
| Virus Shedding | 2 | 2020 | 5834 | 0.28 | Why? |
| HIV | 4 | 2020 | 1116 | 0.27 | Why? |
| Hepatitis B Vaccines | 1 | 2005 | 245 | 0.25 | Why? |
| Medicaid | 2 | 2018 | 492 | 0.25 | Why? |
| Anti-Retroviral Agents | 3 | 2019 | 1099 | 0.23 | Why? |
| Anti-HIV Agents | 4 | 2017 | 2209 | 0.19 | Why? |
| Immunization, Passive | 8 | 2021 | 10067 | 0.19 | Why? |
| Plasma | 2 | 2020 | 1809 | 0.19 | Why? |
| Biomedical Research | 1 | 2019 | 5270 | 0.19 | Why? |
| Translocation, Genetic | 1 | 2017 | 40 | 0.18 | Why? |
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2017 | 21 | 0.18 | Why? |
| Coinfection | 2 | 2017 | 6820 | 0.18 | Why? |
| Agammaglobulinemia | 1 | 2020 | 213 | 0.17 | Why? |
| Genetic Diseases, X-Linked | 1 | 2020 | 237 | 0.17 | Why? |
| Lipid Metabolism Disorders | 1 | 2016 | 6 | 0.17 | Why? |
| Arteritis | 1 | 2017 | 23 | 0.17 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2017 | 66 | 0.17 | Why? |
| Insurance Claim Review | 1 | 2017 | 108 | 0.17 | Why? |
| Receptor for Advanced Glycation End Products | 1 | 2018 | 100 | 0.17 | Why? |
| Puerto Rico | 1 | 2017 | 177 | 0.16 | Why? |
| Lipoproteins, HDL | 1 | 2018 | 154 | 0.16 | Why? |
| Sustained Virologic Response | 1 | 2018 | 378 | 0.16 | Why? |
| Organizational Culture | 1 | 2019 | 395 | 0.15 | Why? |
| Viral Load | 5 | 2017 | 15850 | 0.15 | Why? |
| United States | 11 | 2021 | 46150 | 0.15 | Why? |
| Interleukin-1beta | 1 | 2020 | 992 | 0.14 | Why? |
| Chlamydia Infections | 1 | 2017 | 248 | 0.14 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2014 | 952 | 0.14 | Why? |
| Interleukin-8 | 1 | 2020 | 964 | 0.14 | Why? |
| Hepatitis B e Antigens | 1 | 2014 | 99 | 0.13 | Why? |
| Organophosphonates | 1 | 2014 | 85 | 0.13 | Why? |
| Placebos | 1 | 2017 | 629 | 0.13 | Why? |
| Career Choice | 1 | 2019 | 498 | 0.13 | Why? |
| Deoxycytidine | 1 | 2014 | 116 | 0.13 | Why? |
| Gonorrhea | 1 | 2017 | 315 | 0.13 | Why? |
| Wearable Electronic Devices | 1 | 2021 | 694 | 0.13 | Why? |
| Emtricitabine | 1 | 2014 | 202 | 0.13 | Why? |
| Personnel Selection | 1 | 2019 | 512 | 0.13 | Why? |
| Lamivudine | 1 | 2014 | 210 | 0.12 | Why? |
| Biomarkers | 5 | 2018 | 23361 | 0.12 | Why? |
| Schools, Medical | 1 | 2019 | 793 | 0.11 | Why? |
| Insurance, Health | 1 | 2017 | 634 | 0.11 | Why? |
| Heart Rate | 1 | 2021 | 1527 | 0.11 | Why? |
| Adenine | 1 | 2014 | 463 | 0.11 | Why? |
| Tenofovir | 1 | 2014 | 449 | 0.10 | Why? |
| Cardiovascular System | 1 | 2018 | 750 | 0.10 | Why? |
| Humans | 41 | 2021 | 930598 | 0.10 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2020 | 2483 | 0.10 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.10 | Why? |
| Female | 26 | 2021 | 380317 | 0.10 | Why? |
| New York City | 5 | 2020 | 7432 | 0.10 | Why? |
| HIV-1 | 3 | 2021 | 3365 | 0.10 | Why? |
| Lipids | 1 | 2016 | 1079 | 0.10 | Why? |
| Adult | 21 | 2021 | 244371 | 0.10 | Why? |
| Pain Management | 1 | 2018 | 854 | 0.10 | Why? |
| Research Personnel | 1 | 2019 | 1037 | 0.09 | Why? |
| Double-Blind Method | 2 | 2017 | 5988 | 0.09 | Why? |
| Male | 25 | 2021 | 367725 | 0.09 | Why? |
| Disabled Persons | 1 | 2019 | 1152 | 0.09 | Why? |
| National Institutes of Health (U.S.) | 2 | 2021 | 443 | 0.09 | Why? |
| Analgesics, Opioid | 1 | 2018 | 1070 | 0.09 | Why? |
| Middle Aged | 21 | 2021 | 270681 | 0.08 | Why? |
| Proteomics | 1 | 2018 | 2481 | 0.08 | Why? |
| Continuity of Patient Care | 1 | 2017 | 1574 | 0.08 | Why? |
| Hospitals | 3 | 2021 | 11793 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 1510 | 0.08 | Why? |
| Immunologic Memory | 1 | 2018 | 3362 | 0.08 | Why? |
| Piperazines | 1 | 2009 | 445 | 0.08 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.08 | Why? |
| Herpesvirus 4, Human | 1 | 2009 | 387 | 0.07 | Why? |
| Young Adult | 8 | 2020 | 93724 | 0.07 | Why? |
| Severity of Illness Index | 4 | 2020 | 48226 | 0.07 | Why? |
| Antibodies, Fungal | 1 | 2005 | 49 | 0.07 | Why? |
| Patient Care | 1 | 2016 | 1664 | 0.07 | Why? |
| Logistic Models | 2 | 2014 | 9089 | 0.07 | Why? |
| Organ Transplantation | 1 | 2020 | 2616 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2021 | 253789 | 0.07 | Why? |
| Treatment Outcome | 7 | 2020 | 51732 | 0.07 | Why? |
| Epstein-Barr Virus Infections | 1 | 2009 | 366 | 0.07 | Why? |
| Hepatitis B Antibodies | 1 | 2005 | 142 | 0.07 | Why? |
| Survivors | 1 | 2017 | 2619 | 0.07 | Why? |
| Cryptococcus neoformans | 1 | 2005 | 71 | 0.07 | Why? |
| Adolescent | 7 | 2020 | 86841 | 0.07 | Why? |
| Meningitis, Cryptococcal | 1 | 2005 | 79 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.07 | Why? |
| Lymphoma | 1 | 2009 | 522 | 0.06 | Why? |
| Inflammation | 3 | 2021 | 13255 | 0.06 | Why? |
| Education, Medical | 1 | 2019 | 2461 | 0.06 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2009 | 533 | 0.06 | Why? |
| Antibodies, Neutralizing | 2 | 2020 | 25288 | 0.06 | Why? |
| Antibodies, Viral | 4 | 2020 | 51949 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Neoplasms | 2 | 2020 | 17251 | 0.06 | Why? |
| Postoperative Complications | 1 | 2020 | 5861 | 0.06 | Why? |
| Aged | 12 | 2021 | 215776 | 0.06 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.06 | Why? |
| Healthcare Disparities | 1 | 2019 | 3893 | 0.06 | Why? |
| Pyrimidines | 1 | 2009 | 1557 | 0.05 | Why? |
| Mass Screening | 2 | 2017 | 8005 | 0.05 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.05 | Why? |
| Aging | 1 | 2017 | 3581 | 0.05 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.05 | Why? |
| Hospital Mortality | 2 | 2020 | 22087 | 0.05 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.05 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.05 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.05 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.05 | Why? |
| Transfusion Reaction | 1 | 2020 | 245 | 0.04 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.04 | Why? |
| Stakeholder Participation | 1 | 2021 | 481 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.04 | Why? |
| RNA, Viral | 1 | 2005 | 32276 | 0.04 | Why? |
| Geography, Medical | 1 | 2020 | 537 | 0.04 | Why? |
| Markov Chains | 1 | 2019 | 502 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| Data Interpretation, Statistical | 1 | 2021 | 657 | 0.04 | Why? |
| Practice Guidelines as Topic | 1 | 2021 | 15421 | 0.04 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.04 | Why? |
| Kruppel-Like Transcription Factors | 1 | 2016 | 91 | 0.04 | Why? |
| Survival Rate | 2 | 2020 | 9206 | 0.04 | Why? |
| Cohort Studies | 4 | 2020 | 36005 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2014 | 10649 | 0.04 | Why? |
| Circadian Rhythm | 1 | 2021 | 607 | 0.04 | Why? |
| Multivariate Analysis | 1 | 2005 | 5440 | 0.03 | Why? |
| Advisory Committees | 1 | 2021 | 1418 | 0.03 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.03 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.03 | Why? |
| Interprofessional Relations | 1 | 2021 | 1013 | 0.03 | Why? |
| Risk-Taking | 1 | 2017 | 508 | 0.03 | Why? |
| Health Services Accessibility | 1 | 2017 | 10697 | 0.03 | Why? |
| New York | 1 | 2021 | 2488 | 0.03 | Why? |
| Mental Health | 1 | 2019 | 15770 | 0.03 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.03 | Why? |
| Propensity Score | 1 | 2020 | 2690 | 0.03 | Why? |
| Drug Approval | 1 | 2021 | 1325 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Blood Transfusion | 1 | 2020 | 1399 | 0.03 | Why? |
| Homosexuality, Male | 1 | 2019 | 1158 | 0.03 | Why? |
| Aged, 80 and over | 4 | 2020 | 88759 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.02 | Why? |
| Disease Progression | 2 | 2019 | 13580 | 0.02 | Why? |
| Residence Characteristics | 1 | 2020 | 1927 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2021 | 2654 | 0.02 | Why? |
| Patient Compliance | 1 | 2019 | 1468 | 0.02 | Why? |
| Sexual and Gender Minorities | 1 | 2019 | 1019 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2021 | 4758 | 0.02 | Why? |
| Lymphopenia | 1 | 2021 | 2669 | 0.02 | Why? |
| Safety | 1 | 2016 | 1583 | 0.02 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2021 | 3228 | 0.02 | Why? |
| Lymphocytes | 1 | 2020 | 3056 | 0.02 | Why? |
| Electronic Health Records | 1 | 2020 | 3492 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2020 | 3493 | 0.02 | Why? |
| Neutralization Tests | 1 | 2020 | 6698 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 2426 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2019 | 6543 | 0.02 | Why? |
| Antibodies, Monoclonal | 1 | 2005 | 8041 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.02 | Why? |
| Antigens, Fungal | 1 | 2005 | 106 | 0.02 | Why? |
| Research | 1 | 2017 | 2115 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Health Promotion | 1 | 2017 | 2020 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2017 | 3388 | 0.02 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Phylogeny | 1 | 2020 | 13341 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Area Under Curve | 1 | 2005 | 2564 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Mice | 1 | 2005 | 21357 | 0.00 | Why? |
| Animals | 1 | 2005 | 78931 | 0.00 | Why? |